China’s Junshi Hits New High on Tie-Up With US Anti-Cancer Drug Maker Revitope
Dou Shicong
DATE:  Jul 14 2020
/ SOURCE:  Yicai
China’s Junshi Hits New High on Tie-Up With US Anti-Cancer Drug Maker Revitope China’s Junshi Hits New High on Tie-Up With US Anti-Cancer Drug Maker Revitope

(Yicai Global) July 14 -- Shares in Hong Kong-listed Junshi Biosciences, which is preparing to also go public on the Shanghai Stock Exchange’s Star Market tomorrow, hit a record high today on the news that the Chinese biopharmaceutical firm is to collaborate with US drug maker Revitope Oncology to develop innovative anti-cancer drugs and receive worldwide exclusive licensing rights on them.

Junshi [HKG:1877] hiked by nearly 6 percent on market opening today, hitting a record high of HKD64.70 (USD8.35). It was later dragged down by the bourse’s general downward trend, to close up 3.03 percent at HKD62.85 with a market capitalization of HKD49.3 billion (USD6.3 billion). The Hang Seng Index dipped 1.14 percent.

“Revitope will leverage its proprietary protein engineering platform together with Junshi’s novel antibody components to develop first-in-class dual-antigen targeting cancer therapies,” according to the statement released by Shanghai-based Junshi today. Junshi, which will lead the clinical research, will be granted exclusive worldwide distribution rights on the products developed.

The Chinese drug maker will invest USD10 million in Massachusetts-based Revitope to acquire 9.99 percent equity, the statement said. It will also offer a downpayment of an unspecified amount to Revitope, as well as possible future milestone payments and sales commissions.

Junshi, most known for its anti-cancer drug Toripalimab, has attracted a lot of attention in recent months thanks to its pioneering work fighting the novel coronavirus. Its Covid-19 antibody drug, co-developed with a number of other Chinese scientific research institutions, was the first such drug to be greenlighted by the country’s National Medical Products Administration to proceed with clinical trials.

The firm’s heavy emphasis on research and development has seen it burn through CNY1.9 billion (USD271.3 million) in the last four years.

Editor: Kim Taylor

Follow Yicai Global on
Keywords:   Junshi Biosciences,Revitope Oncology,Cancer Medicine